Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: May 12, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, sec-filing
TL;DR
Addex Therapeutics filed a 6-K on May 12, 2025, incorporating a press release into its SEC filings.
AI Summary
On May 12, 2025, Addex Therapeutics Ltd. issued a press release, attached as Exhibit 99.1 to this Form 6-K filing. This press release is incorporated by reference into the company's existing registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration Nos. 333-255124 and 333-27).
Why It Matters
This filing indicates that Addex Therapeutics has issued a press release, which may contain important updates for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain new financial data or significant operational announcements.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- May 12, 2025 (date) — Date of press release and filing
- Exhibit 99.1 (document) — Attached press release
- Form F-3 (document) — Registration statement
- 333-255089 (registration_number) — Form F-3 registration number
- Form S-8 (document) — Registration statement
- 333-255124 (registration_number) — Form S-8 registration number
- 333-27 (registration_number) — Form S-8 registration number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report a press release issued by Addex Therapeutics Ltd. on May 12, 2025, and to incorporate it by reference into the company's existing registration statements.
What is the date of the press release mentioned in the filing?
The press release was dated May 12, 2025.
Which registration statements are updated by this filing?
This filing incorporates the press release into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statements on Form S-8 (Registration Nos. 333-255124 and 333-27).
What is the filing type and submission type?
The filing type is Form 6-K, and the conformed submission type is also 6-K.
Where is Addex Therapeutics Ltd. located?
Addex Therapeutics Ltd. is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding Addex Therapeutics Ltd. (ADXN).